grant
the contribution of APOE4 mediated bioenergetic deficits in the cerebrovascular dysfunction in Alzheimer's disease
Organization JAMES A. HALEY VA MEDICAL CENTERLocation TAMPA, UNITED STATESPosted 1 Apr 2024Deadline 31 Mar 2029
VANIHUS FederalResearch GrantFY2025AD dementiaAPOEAPOE e4APOE-ε4APOEε4AQP4 proteinAbeta clearanceAbscissionAcetyl Coenzyme A CarboxylaseAcetyl-CoA CarboxylaseAgeAgingAllelesAllelomorphsAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer risk factorAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimer's disease patientAlzheimer's disease riskAlzheimer's disease therapyAlzheimer's patientAlzheimer's therapyAlzheimers DementiaAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid Protein A4Amyloid beta-ProteinAmyloid βAmyloid β clearanceAmyloid β-PeptideAmyloid β-ProteinAnimalsApo-EApoE proteinApolipoprotein EAstrocytesAstrocytusAstrogliaAβAβ burdenAβ clearanceBioenergeticsBleedingBlood - brain barrier anatomyBlood VesselsBlood-Brain BarrierBrainBrain Nervous SystemBrain VascularBrain Vascular DisordersCell BodyCellsCerebrovascular DiseaseCerebrovascular DisordersCerebrovascular systemChemicalsCouplesCre Lox technologyCre LoxP systemCre lox recombinationCre lox recombination systemCre lox systemCre recombinase/LoxP technologyCre systemD-GlucoseDetectionDeteriorationDextroseEarly InterventionEncephalonEnergy-Generating ResourcesEnvironmentEnzyme GeneEnzymesEquilibriumExcisionExtirpationFailureFatsFatty Acid Metabolism PathwayFatty AcidsFatty acid glycerol estersGenesGeneticGenetic predisposing factorGenotypeGlucoseGlycolysisHemato-Encephalic BarrierHemorrhageHumanImpairmentIndividualInflammationIntermediary MetabolismIntracranial Vascular DiseasesIntracranial Vascular DisordersKetonesKnock-outKnockoutL CarnitineLevocarnitineLinkMediatingMetabolic ProcessesMetabolismMiceMice MammalsMissionMitochondriaModern ManMolecularMurineMusNerve CellsNerve UnitNeural CellNeurocyteNeuronsNutrientOxidative StressPathogenesisPathway interactionsPersonsPrimary Senile Degenerative DementiaProcessPropertyRemovalReportingResearchRiskStable Isotope LabelingSurgical RemovalSystemTauopathiesTestingTherapeuticTherapeutic InterventionTimeTransportationVitamin B TWaste ProductsWorka beta peptidea-beta burdena-beta peptide clearanceabetaabeta burdenabeta peptide clearanceacylcarnitineage associatedage associated effectsage correlatedage dependentage effectage linkedage relatedage related effectsage specificagesaging effectalzheimer riskamyloid betaamyloid beta clearanceamyloid beta peptide clearanceamyloid burdenamyloid pathologyamyloid-b proteinapo E-4apo E4apo epsilon4apoE epsilon 4apoE-4apoE4apolipoprotein E epsilon 4apolipoprotein E-4apolipoprotein E4aquaporin 4astrocytic gliabalancebalance functionbeta amyloid burdenbeta amyloid fibrilblood lossblood vessels in the brainbloodbrain barrierbrain blood vesselsbrain endothelial cellbrain microvascular endothelial cellbrain parenchymabrain vascular diseasebrain vascular dysfunctionbrain vascular endothelial cellbrain vascular pathologybrain vascular pathophysiologybrain vasculatureburden of diseaseburden of illnesscerebral angiopathycerebral blood vesselcerebral endothelial cellcerebral microvascular endothelial cellcerebral vascularcerebral vascular diseasecerebral vascular dysfunctioncerebral vascular endothelial cellcerebral vascular pathologycerebral vasculaturecerebral vasculopathycerebro-vascularcerebrovascularcerebrovascular abnormalitycerebrovascular contributions to Alzheimer's diseasecerebrovascular defectcerebrovascular disease pathologycerebrovascular dysfunctioncerebrovascular dysfunction in Alzheimer's diseasecerebrovascular pathologycerebrovascular pathophysiologycerebrovascular vesselscerebrovasculaturecerebrovasculopathycognitive functiondisease burdenenergy sourceexperiencefatty acid metabolismfatty acid oxidationfatty acid transportflexibilityflexiblegenetic risk factorglucose metabolismglucose transportglucose uptakeglymphatic clearanceglymphatic functionimpact of ageimprovedinfluence of ageinherited factorinhibitorinsightintervention therapyintracranial vascular dysfunctionknock-downknockdownknockout genelipidomicslong chain fatty acidmetabolism measurementmetabolomicsmetabonomicsmitochondrialmouse modelmurine modelneuro-vascular unitneuronalneuropathologic tauneuropathological tauneurovascular unitnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoxidationpathwaypatient living with Alzheimer's diseasepatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseasepre-clinicalpreclinicalprimary degenerative dementiaresectionsenile dementia of the Alzheimer typesoluble amyloid precursor proteintau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau neurodegenerative diseasetau neuropathologytau pathologytau pathophysiologytau proteinopathytau related neurodegenerationtau-induced pathologytauopathic neurodegenerative disordertauopathytherapeutic agent developmenttherapeutic developmenttherapeutic targettranscriptomicsvascularvascular burden on Alzheimer's diseasevascular contribution to Alzheimer's Diseasevascular contributions to ADvascular contributions to Alzheimer'svascular contributor to Alzheimer's diseasevascular dysfunction in ADvascular dysfunction in Alzheimer's diseasewastingβ-amyloid burdenβamyloid burden
Description preview
The apolipoprotein E (APOE) E4 allele is one of the main genetic risk factors for Alzheimer’s disease (AD) and
an important contributor to cerebrovascular (CV) dysfunction, which is a major component of AD pathogenesis.
Recent advances in AD research suggest that E4 carriers have an age-dependent vulnerability in supplying
glucose to the brain,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click